PDCD1 and neoplasm: Of relevance, tumor infiltrating lymphocytes were found in the regression bed of neo-adjuvant anti-PD-1 treated resectable NSCLC patients [10], whereas the inability of T cells to enter in the tumor bed, has been indicated as a mechanism of resistance to cancer immunotherapy [35].